$MIST News
Last published 1w ago
- 1w agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in
- 1w agoMISTMilestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026GlobeNewswireMONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 1w agoMISTNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter AblationGlobeNewswireMONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 3w agoMISTMilestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology ConferencesGlobeNewswireMONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 2mo agoMISTMilestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United StatesGlobeNewswireEverest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals
- 2mo agoMISTMilestone Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireMONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 2mo agoMISTMilestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between EpisodesGlobeNewswireMONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 2mo agoMISTMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)GlobeNewswireReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced
- 3mo agoMISTMilestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireOver 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial
- 3mo agoMISTMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireMONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 4mo agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in
- 4mo agoACOGMISTCBAYONCTAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced
- 6mo agoMISTMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQGlobeNewswireMONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative
- 6mo agoMISTMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress
- 6mo agoMISTMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026GlobeNewswireMONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
- 7mo agoMIST25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - MILESTONE PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good afternoon, everyone, and welcome back to the 25th Annual Needham Healthcare Conference. My name is John Giacomo. I'm a member of the Biopharma Research Team here at Needham. For our next session, I'm exci
- 7mo agoMISTMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTGlobeNewswireMONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
- 7mo agoMISTMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireMONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development of commercialization of innovative
- 7mo agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a
- 7mo agoMISTMilestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesGlobeNewswireMONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative
- 8mo agoMISTMilestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific SessionGlobeNewswireMONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative
- 8mo agoMISTMilestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026GlobeNewswireMONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business
- 8mo agoMISTTD Cowen 46th Annual Health Care Conference - MILESTONE PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everybody. Thank you for joining us here today at the TD Cowan 46 Annual Healthcare Conference. My name is Athena Chin as part of the biotech team, and I'm pleased to introduce Milestone Pharmaceuticals wit
- 8mo agoMISTMilestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireMONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer,
- 9mo agoMISTMilestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance OfficerGlobeNewswireMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr.
- 9mo agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a
- 9mo agoMISTMilestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)GlobeNewswireCARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured patientsLaunch
- 10mo agoATRMISTAptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)Business WireNovel treatment for PSVT developed with Milestone Pharmaceuticals Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its
- 11mo agoMISTMilestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)GlobeNewswireFirst FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of
- 11mo agoMISTApproval of Cardamyst, Nda #218571 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 12/12/2025; Drug Name: Cardamyst, Nda #218571; Active Ingredients: ETRIPAMIL; Company: Milestone Pharmaceuticals Usa, Inc.; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 218571
- 11mo agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a
- 12mo agoMISTMilestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewswirePDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA
- 1y agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a
- 1y agoMISTMilestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025GlobeNewswireMONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative
- 1y agoMISTMilestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025GlobeNewswireMONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
- 1y agoMISTMilestone® Pharmaceuticals to Present at Upcoming ConferencesGlobeNewswireMONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells
- 1y agoMISTMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewswireFDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved
- 1y agoMISTMilestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common WarrantsGlobeNewswireMONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of
- 1y agoMISTMilestone Pharmaceuticals Announces Proposed Public OfferingGlobeNewswireMONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST) today announced that it has commenced an underwritten public offering (the
- 1y agoMISTMilestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayGlobeNewswireNew PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals
- 1y agoMISTMilestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingGlobeNewswireMONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)'s Complete
- 1y agoMISTMilestone Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireMONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer,
- 1y agoMISTMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewswireResolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone
- 1y agoACOGCBAYMISTONCTAlpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John HavensBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 1y agoMISTFDA Issues Complete Response Letter for Etripamil for PSVTGlobeNewswireCRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE
- 1y agoMISTMilestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of CardiologyGlobeNewswireMONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
- 1y agoMISTMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewswireFDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025
- 1y agoMISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a
- 1y agoMISTMilestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireMONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health
- 1y agoMISTMilestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for EtripamilGlobeNewswireMONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative